Clinical trial
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy…
NCT00392990 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00392990 |
|---|---|
| Title | Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma |
| Official title | A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Regimen A, Regimen B |
| Enrollment | 25 |
| Start date | Feb 6, 2007 |
| Primary completion | Dec 3, 2011 |
| Completion | May 28, 2013 |
| First posted | Oct 26, 2006 |
| Last update posted | Oct 15, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: